TABLE OF CONTENTS
1 INTRODUCTION 76
1.1 OBJECTIVES OF THE STUDY 76
1.2 MARKET DEFINITION 76
1.3 OVERVIEW OF GLOBAL MIGRAINE TREATMENT MARKET 76
1.4 LIMITATIONS 79
1.5 MARKETS COVERED 79
2 MARKET SEGMENTATION 84
2.1 MARKETS COVERED 84
2.2 GEOGRAPHICAL SCOPE 85
2.3 YEARS CONSIDERED FOR THE STUDY 86
2.4 CURRENCY AND PRICING 86
2.5 DBMR TRIPOD DATA VALIDATION MODEL 87
2.6 MULTIVARIATE MODELLING 90
2.7 TYPES OF MIGRAINE LIFELINE CURVE 90
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 91
2.9 DBMR MARKET POSITION GRID 92
2.10 VENDOR SHARE ANALYSIS 93
2.11 SECONDARY SOURCES 94
2.12 ASSUMPTIONS 94
3 MARKET OVERVIEW 95
3.1 DRIVERS 97
3.1.1 INCREASING PREVALENCE OF MIGRAINE 97
3.1.2 GROWING FEMALE POPULATION 97
3.1.3 DEVELOPMENT OF NOVEL DRUGS 98
3.1.4 RISING AWARENESS PROGRAMS 99
3.1.5 AVAILABILITY OF LARGE NUMBER OF GENERIC DRUGS 99
3.2 RESTRAINTS 101
3.2.1 RECALL OF DRUGS 101
3.2.2 ADVERSE EFFECTS OF DRUGS 101
3.3 OPPORTUNITIES 102
3.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE TREATMENT OF ACUTE MIGRAINE 102
3.3.2 INCREASING R&D INVESTMENT LEADING TO PIPELINE PRODUCTS 102
3.3.3 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS 103
3.4 CHALLENGES 104
3.4.1 USE OF ALTERNATIVE THERAPIES SUCH AS HOMEOPATHY 104
3.4.2 LIMITATIONS OF CURRENT MIGRAINE THERAPIES 105
4 EXECUTIVE SUMMARY 106
5 PREMIUM INSIGHTS 110
6 EPIDEMIOLOGY 112
7 REIMBURSEMENT SCENARIO & REGULATION STATUS 113
7.1 REIMBURSEMENT SCENARIO 113
7.2 REGULATIONS 114
8 PIPELINE ANALYSIS 115
9 IMPACT OF COVID 19 PANDEMIC ON THE MARKET 116
9.1 PRICE IMPACT 116
9.2 IMPACT ON DEMAND 116
9.3 IMPACT ON SUPPLY CHAIN 116
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS 117
9.5 CONCLUSION 117
10 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE 118
10.1 OVERVIEW 119
10.2 EPISODIC 122
10.3 MIGRAINE WITH AURA 123
10.4 CHRONIC 123
10.5 OTHERS 124
11 GLOBAL MIGRAINE TREATMENT MARKET, BY TREATMENT 125
11.1 OVERVIEW 126
11.2 ACUTE/ABORTIVE TREATMENT 129
11.2.1 NONSPECIFIC THERAPIES 130
11.2.1.1 TRIPTANS 130
11.2.1.1.1 SUMATRIPTAN 131
11.2.1.1.2 RIZATRIPTAN 131
11.2.1.1.3 OTHERS 131
11.2.1.2 OPIATES/OPOIDS 131
11.2.1.2.1 VICODIN 132
11.2.1.2.2 OXYCONTIN 132
11.2.1.2.3 PERCOCET 132
11.2.1.2.4 OTHERS 132
11.2.1.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 132
11.2.1.3.1 ASPIRIN 132
11.2.1.3.2 IBUPROFEN 133
11.2.1.3.3 ACETAMINOPHEN 133
11.2.1.3.4 OTHERS 133
11.2.1.4 ERGOT ALKALOID 133
11.2.1.4.1 ERGOTAMINE 133
11.2.1.4.2 LASMIDITAN 133
11.2.1.4.3 DIHYDROERGOTAMINES 134
11.2.1.4.4 OTHERS 134
11.2.1.5 ANTI-NAUSEA 134
11.2.1.5.1 PROCHLORPERAZINE 134
11.2.1.5.2 METOCLOPRAMIDE 134
11.2.1.5.3 CHLORPROMAZINE 134
11.2.1.5.4 OTHERS 135
11.2.1.6 OTHERS 135
11.2.2 ADJUNCTIVE THERAPIES 135
11.2.2.1 ANTIEMETICS 135
11.2.2.2 SEDATIVES 135
11.2.2.3 OTHERS 136
11.2.3 OTHERS 136
11.2.3.1 INTRANASAL LIDOCAINE 136
11.2.3.2 STEROIDS 136
11.2.3.3 OTHERS 136
11.3 PREVENTIVE/PROPHYLACTIC TREATMENT 136
11.3.1 ANTICONVULSANTS 138
11.3.1.1 TOPAMAX (TOPIRAMATE) 138
11.3.1.2 TROKENDI (TOPIRAMATE) 138
11.3.1.3 DEPAKOTE (DIVALPROEX SODIUM) 138
11.3.1.4 QUDEXY XR (TOPIRAMATE) 138
11.3.1.5 OTHERS 139
11.3.2 CALCITONIN GENE-RELATED PEPTIDE THERAPY 139
11.3.2.1 ERENUMAB-AOOE 139
11.3.2.2 GALCANEZUMAB 139
11.3.2.3 FREMANEZUMAB-VFRM 139
11.3.2.4 OTHERS 139
11.3.3 SELECTIVE SEROTONIN RECEPTOR AGONISTS 140
11.3.3.1 SUMATRIPTAN 140
11.3.3.2 RIZATRIPTAN 140
11.3.3.3 ZOLMITRIPTAN 140
11.3.3.4 ELETRIPTAN 140
11.3.3.5 FROVATRIPTAN 141
11.3.3.6 NARATRIPTAN 141
11.3.3.7 ALMOTRIPTAN MALATE 141
11.3.3.8 OTHERS 141
11.3.4 ANTIDEPRESSANTS 141
11.3.4.1 AMITRIPTYLINE 141
11.3.4.2 NORTRIPTYLINE 141
11.3.4.3 OTHERS 142
11.3.5 NSAIDS 142
11.3.5.1 NAPROXEN SODIUM 142
11.3.5.2 NAPROXEN 142
11.3.5.3 KETOPROFEN 142
11.3.5.4 FENOPROFEN 142
11.3.5.5 OTHERS 142
11.3.6 BLOOD PRESSURE-LOWERING MEDICATIONS 143
11.3.6.1 BETA BLOCKERS 143
11.3.6.1.1 PROPRANAOLOL 144
11.3.6.1.2 TIMOLOL 144
11.3.6.1.3 OTHERS 144
11.3.6.2 CALCIUM-CHANNEL BLOCKERS 144
11.3.6.2.1 VERAPAMIL 144
11.3.6.2.2 NIMODIPINE 144
11.3.6.2.3 OTHERS 145
11.3.7 ANGIOTENSIN BLOCKERS: ACE-IS/ARBS 145
11.3.7.1 CANDESARTAN 145
11.3.7.2 TELMISARTAN 145
11.3.7.3 OTHERS 145
11.3.8 OTHERS 146
11.4 NON-PHARMACOLOGICAL THERAPIES 146
11.4.1 ACUPUNCTURE 147
11.4.2 BIOFEEDBACK TECHNIQUES 147
11.4.3 COGNITIVE BEHAVIOR THERAPY 147
11.4.4 MASSAGE 148
11.4.5 RELAXATION 148
11.4.6 OTHERS 148
11.5 DEVICES 148
11.5.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 149
11.5.2 OTHERS 149
12 GLOBAL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 150
12.1 OVERVIEW 151
12.2 ORAL 154
12.3 PARENTERAL 155
12.4 NASAL SPRAYS 156
12.5 OTHERS 157
?
13 GLOBAL MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE 158
13.1 OVERVIEW 159
13.2 PRESCRIPTION 162
13.3 OVER THE COUNTER 163
14 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPE 164
14.1 OVERVIEW 165
14.2 GENERIC 168
14.3 BRANDED 169
15 GLOBAL MIGRAINE TREATMENT MARKET, BY END USER 170
15.1 OVERVIEW 171
15.2 HOSPITALS 174
15.3 CLINICS 175
15.4 HOMECARE 176
15.5 OTHERS 176
16 GLOBAL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 177
16.1 OVERVIEW 178
16.2 HOSPITAL PHARMACIES 180
16.3 RETAIL PHARMACIES 181
16.4 ONLINE PHARMACIES 182
16.5 OTHERS 182
17 GLOBAL MIGRAINE TREATMENT MARKET, BY GEOGRAPHY 183
17.1 OVERVIEW 184
17.2 NORTH AMERICA 189
17.2.1 U.S. 200
17.2.2 CANADA 208
17.2.3 MEXICO 216
17.3 EUROPE 224
17.3.1 GERMANY 236
17.3.2 U.K. 244
17.3.3 FRANCE 252
17.3.4 ITALY 260
17.3.5 SPAIN 268
17.3.6 NETHERLANDS 276
17.3.7 RUSSIA 284
17.3.8 SWITZERLAND 292
17.3.9 BELGIUM 300
17.3.10 TURKEY 308
17.3.11 AUSTRIA 316
17.3.12 NORWAY 324
17.3.13 HUNGARY 332
17.3.14 LITHUANIA 340
17.3.15 IRELAND 348
17.3.16 POLAND 356
17.3.17 REST OF EUROPE 364
17.4 ASIA-PACIFIC 365
17.4.1 CHINA 377
17.4.2 JAPAN 385
17.4.3 INDIA 393
17.4.4 SOUTH KOREA 401
17.4.5 AUSTRALIA 409
17.4.6 SINGAPORE 417
17.4.7 INDONESIA 425
17.4.8 THAILAND 433
17.4.9 MALAYSIA 441
17.4.10 PHILIPPINES 449
17.4.11 VIETNAM 457
17.4.12 REST OF ASIA-PACIFIC 465
17.5 SOUTH AMERICA 466
17.5.1 BRAZIL 477
17.5.2 ARGENTINA 485
17.5.3 PERU 493
17.5.4 REST OF SOUTH AMERICA 501
17.6 MIDDLE EAST & AFRICA 502
17.6.1 SAUDI ARABIA 514
17.6.2 SOUTH AFRICA 522
17.6.3 UAE 530
17.6.4 ISRAEL 538
17.6.5 KUWAIT 546
17.6.6 EGYPT 554
17.6.7 REST OF MIDDLE EAST & AFRICA 562
18 GLOBAL MIGRAINE TREATMENT MARKET, COMPANY LANDSCAPE 563
18.1 COMPANY SHARE ANALYSIS: GLOBAL 563
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 564
18.3 COMPANY SHARE ANALYSIS: EUROPE 565
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 566
?
19 SWOT ANALYSIS AND DATA BRIDGE MARKET RESEARCH ANALYSIS 567
19.1 SWOT ANALYSIS 567
19.1.1 STRENGTH 567
19.1.1.1 STRONG PRODUCT PORTFOLIO 567
19.1.1.2 GLOBAL COMMERCIAL PRESENCE IN EMERGING MARKETS 567
19.1.2 WEAKNESS 568
19.1.2.1 DEPENDENCY ON THIRD PARTIES FOR RESEARCH AND DEVELOPMENT 568
19.1.2.2 LITIGATION AND GOVERNMENT INVESTIGATION 568
19.1.3 OPPORTUNITY 568
19.1.3.1 EXPANDING BUSINESS THOROUGH THEIR SUBSIDIARIES 568
19.1.3.2 STRATEGIC INITIATIVES 569
19.1.4 THREAT 569
19.1.4.1 COMPETITIVE ENVIRONMENT 569
19.2 GLOBAL MIGRAINE TREATMENT MARKET: DBMR ANALYSIS 570
20 COMPANY PROFILE 571
20.1 AMGEN INC. 571
20.1.1 COMPANY SNAPSHOT 571
20.1.2 REVENUE ANALYSIS 572
20.1.3 COMPANY SHARE ANALYSIS 572
20.1.4 PRODUCT PORTFOLIO 572
20.1.5 RECENT DEVELOPMENTS 573
20.2 ELI LILLY AND COMPANY 574
20.2.1 COMPANY SNAPSHOT 574
20.2.2 REVENUE ANALYSIS 575
20.2.3 COMPANY SHARE ANALYSIS 575
20.2.4 PRODUCT PORTFOLIO 576
20.2.5 RECENT DEVELOPMENTS 576
20.3 GLAXOSMITHKLINE PLC. 577
20.3.1 COMPANY SNAPSHOT 577
20.3.2 REVENUE ANALYSIS 578
20.3.3 COMPANY SHARE ANALYSIS 578
20.3.4 PRODUCT PORTFOLIO 579
20.3.5 RECENT DEVELOPMENTS 579
20.4 NOVARTIS AG 580
20.4.1 COMPANY SNAPSHOT 580
20.4.2 REVENUE ANALYSIS 581
20.4.3 COMPANY SHARE ANALYSIS 581
20.4.4 PRODUCT PORTFOLIO 582
20.4.5 RECENT DEVELOPMENTS 582
?
20.5 BAYER AG 583
20.5.1 COMPANY SNAPSHOT 583
20.5.2 REVENUE ANALYSIS 584
20.5.3 COMPANY SHARE ANALYSIS 584
20.5.4 PRODUCT PORTFOLIO 585
20.5.5 RECENT DEVELOPMENT 585
20.6 ALLERGAN 586
20.6.1 COMPANY SNAPSHOT 586
20.6.2 REVENUE ANALYSIS 587
20.6.3 PRODUCT PORTFOLIO 587
20.6.4 RECENT DEVELOPMENTS 588
20.7 ABBOTT 589
20.7.1 COMPANY SNAPSHOT 589
20.7.2 REVENUE ANALYSIS 590
20.7.3 PRODUCT PORTFOLIO 590
20.7.4 RECENT DEVELOPMENTS 591
20.8 ALLODYNIC THERAPEUTICS, LLC 592
20.8.1 COMPANY SNAPSHOT 592
20.8.2 PRODUCT PORTFOLIO 592
20.8.3 RECENT DEVELOPMENT 592
20.9 AOBIOME 593
20.9.1 COMPANY SNAPSHOT 593
20.9.2 PRODUCT PORTFOLIO 593
20.9.3 RECENT DEVELOPMENTS 593
20.10 ASTRAZENECA 594
20.10.1 COMPANY SNAPSHOT 594
20.10.2 REVENUE ANALYSIS 595
20.10.3 PRODUCT PORTFOLIO 595
20.10.4 RECENT DEVELOPMENTS 596
20.11 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA) 597
20.11.1 COMPANY SNAPSHOT 597
20.11.2 REVENUE ANALYSIS 597
20.11.3 PRODUCT PORTFOLIO 598
20.11.4 RECENT DEVELOPMENTS 598
20.12 BAUSCH HEALTH COMPANIES INC. 599
20.12.1 COMPANY SNAPSHOT 599
20.12.2 REVENUE ANALYSIS 600
20.12.3 PRODUCT PORTFOLIO 600
20.12.4 RECENT DEVELOPMENT 600
?
20.13 BIOHAVEN PHARMACEUTICALS 601
20.13.1 COMPANY SNAPSHOT 601
20.13.2 REVENUE ANALYSIS 601
20.13.3 PRODUCT PORTFOLIO 602
20.13.4 RECENT DEVELOPMENTS 602
20.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 603
20.14.1 COMPANY SNAPSHOT 603
20.14.2 REVENUE ANALYSIS 603
20.14.3 PRODUCT PORTFOLIO 604
20.14.4 RECENT DEVELOPMENTS 604
20.15 CATALENT, INC 605
20.15.1 COMPANY SNAPSHOT 605
20.15.2 REVENUE ANALYSIS 605
20.15.3 PRODUCT PORTFOLIO 606
20.15.4 RECENT DEVELOPMENTS 606
20.16 DR. REDDY’S LABORATORIES LTD. 607
20.16.1 COMPANY SNAPSHOT 607
20.16.2 REVENUE ANALYSIS 608
20.16.3 PRODUCT PORTFOLIO 608
20.16.4 RECENT DEVELOPMENTS 609
20.17 IMPEL NEUROPHARMA, INC. 610
20.17.1 COMPANY SNAPSHOT 610
20.17.2 PRODUCT PORTFOLIO 610
20.17.3 RECENT DEVELOPMENTS 611
20.18 LUNDBECK 612
20.18.1 COMPANY SNAPSHOT 612
20.18.2 REVENUE ANALYSIS 613
20.18.3 PRODUCT PORTFOLIO 613
20.18.4 RECENT DEVELOPMENTS 614
20.19 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 615
20.19.1 COMPANY SNAPSHOT 615
20.19.2 REVENUE ANALYSIS 616
20.19.3 PRODUCT PORTFOLIO 616
20.19.4 RECENT DEVELOPMENTS 617
20.20 NEURELIS, INC. 618
20.20.1 COMPANY SNAPSHOT 618
20.20.2 PRODUCT PORTFOLIO 618
20.20.3 RECENT DEVELOPMENTS 618
?
20.21 OTSUKA PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF OTSUKA HOLDINGS CO., LTD.) 619
20.21.1 COMPANY SNAPSHOT 619
20.21.2 REVENUE ANALYSIS 619
20.21.3 PRODUCT PORTFOLIO 620
20.21.4 RECENT DEVELOPMENTS 620
20.22 PFIZER INC. 621
20.22.1 COMPANY SNAPSHOT 621
20.22.2 REVENUE ANALYSIS 622
20.22.3 PRODUCT PORTFOLIO 622
20.22.4 RECENT DEVELOPMENTS 623
20.23 SUN PHARMACEUTICAL INDUSTRIES LTD. 624
20.23.1 COMPANY SNAPSHOT 624
20.23.2 REVENUE ANALYSIS 624
20.23.3 PRODUCT PORTFOLIO 625
20.23.4 RECENT DEVELOPMENTS 625
20.24 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.) 626
20.24.1 COMPANY SNAPSHOT 626
20.24.2 REVENUE ANALYSIS 626
20.24.3 PRODUCT PORTFOLIO 627
20.24.4 RECENT DEVELOPMENTS 627
20.25 ZOSANO PHARMA CORPORATION 628
20.25.1 COMPANY SNAPSHOT 628
20.25.2 REVENUE ANALYSIS 628
20.25.3 PRODUCT PORTFOLIO 629
20.25.4 RECENT DEVELOPMENTS 629
21 CONCLUSION 630
22 QUESTIONNAIRE 631
23 RELATED REPORTS 634